AeroBec Autohaler: Uses, Dosage & Side Effects
A breath-actuated inhaled corticosteroid containing beclometasone dipropionate for the preventive treatment of asthma
AeroBec Autohaler is a breath-actuated metered-dose inhaler containing beclometasone dipropionate, an inhaled corticosteroid (ICS) used for the preventive treatment of asthma. Unlike conventional press-and-breathe inhalers, the Autohaler automatically releases a measured dose of medication when the patient breathes in, eliminating the need to coordinate hand actuation with inhalation. This makes it especially suitable for patients who have difficulty using standard metered-dose inhalers. AeroBec Autohaler is a maintenance controller medication that reduces airway inflammation and must be used regularly to prevent asthma attacks—it is not a rescue inhaler for acute symptoms.
Quick Facts: AeroBec Autohaler
Key Takeaways
- AeroBec Autohaler contains beclometasone dipropionate, an inhaled corticosteroid that reduces airway inflammation and prevents asthma attacks when used as daily maintenance therapy as directed by your doctor.
- The breath-actuated (Autohaler) mechanism automatically releases medication when you breathe in, making it easier to use correctly than conventional press-and-breathe metered-dose inhalers.
- It is a preventive medication only—not a rescue inhaler. You must use it every day, even when you feel well, and keep a separate fast-acting bronchodilator for acute asthma symptoms.
- Full therapeutic benefit typically takes approximately 7 to 10 days of regular use, so it is essential to continue treatment consistently even if you do not notice immediate improvement.
- Always rinse your mouth with water and spit out after each inhalation to reduce the risk of oral thrush (candidiasis) and hoarseness, the most common local side effects of inhaled corticosteroids.
What Is AeroBec Autohaler and What Is It Used For?
AeroBec Autohaler contains the active ingredient beclometasone dipropionate, which belongs to a group of medicines called corticosteroids (glucocorticoids). When inhaled directly into the lungs, beclometasone dipropionate exerts powerful anti-inflammatory effects on the airway tissues, reducing the swelling, mucus production, and hyperreactivity that characterize asthma. By controlling this underlying inflammation, the medication prevents asthma symptoms such as wheezing, coughing, chest tightness, and shortness of breath from occurring in the first place.
Beclometasone dipropionate is a prodrug that is converted by esterases in the lung tissue to its active metabolite, beclometasone-17-monopropionate (B-17-MP). This active metabolite binds to intracellular glucocorticoid receptors, forming a receptor-drug complex that translocates to the cell nucleus and modulates the transcription of multiple genes involved in the inflammatory cascade. The result is a broad suppression of inflammatory mediator production, including cytokines (such as interleukin-1, interleukin-4, interleukin-5, and tumor necrosis factor-alpha), chemokines, leukotrienes, and prostaglandins. Additionally, beclometasone inhibits the recruitment and activation of inflammatory cells—including eosinophils, mast cells, T-lymphocytes, macrophages, and neutrophils—within the airway walls.
As an inhaled formulation, beclometasone dipropionate achieves high local concentrations in the airways while minimizing systemic absorption and its associated side effects. The drug undergoes substantial first-pass metabolism in the liver via the cytochrome P450 enzyme CYP3A4, further limiting systemic corticosteroid exposure. This favorable pharmacokinetic profile is a key advantage of inhaled corticosteroids over oral corticosteroid therapy for chronic asthma management, and it is the reason why inhaled corticosteroids like beclometasone are recommended as the foundation of asthma controller therapy by the Global Initiative for Asthma (GINA) and the British Thoracic Society/Scottish Intercollegiate Guidelines Network (BTS/SIGN).
The Autohaler Breath-Actuated Device
The distinctive feature of the AeroBec Autohaler is its breath-actuated delivery mechanism. Unlike conventional metered-dose inhalers (MDIs), which require the patient to simultaneously press down on the canister and breathe in—a coordination that many patients find difficult—the Autohaler uses a spring-loaded mechanism that automatically triggers dose release when it detects the patient's inspiratory airflow through the mouthpiece. This eliminates the need for hand-breath coordination and has been shown in clinical studies to improve drug delivery to the lungs compared to conventional MDIs in patients with poor inhaler technique.
The breath-actuated design is particularly beneficial for several patient groups, including elderly patients with reduced manual dexterity, children who may struggle to coordinate pressing and breathing, patients with arthritis or other conditions affecting hand strength, and anyone who has repeatedly demonstrated poor technique with conventional MDIs despite instruction. Studies published in the European Respiratory Journal and the Journal of Aerosol Medicine have demonstrated that breath-actuated inhalers reduce the common errors associated with conventional MDIs, such as firing the device before or after the inhalation, inhaling too quickly, or failing to generate adequate inspiratory force.
Preventive Use Only
It is essential to understand that AeroBec Autohaler is a preventer medication. It is designed for regular, daily use to control the underlying airway inflammation that causes asthma symptoms. It does not provide rapid relief of acute asthma symptoms and must never be used as a rescue inhaler during an asthma attack. Patients using AeroBec Autohaler should always have a separate short-acting beta2-agonist bronchodilator (such as salbutamol) available for quick relief of breakthrough symptoms. The full preventive benefit of AeroBec Autohaler typically takes approximately 7 to 10 days of consistent, regular use to develop. Patients should continue using the medication as prescribed even when they are symptom-free, as stopping treatment can lead to a return of airway inflammation and asthma symptoms.
Beclometasone dipropionate has been used clinically since the early 1970s and has an extensive safety and efficacy record spanning more than five decades. It is included on the World Health Organization (WHO) Model List of Essential Medicines and is recognized by all major international asthma guidelines—including GINA, BTS/SIGN, NICE, and the National Asthma Education and Prevention Program (NAEPP)—as a first-line controller therapy for persistent asthma of all severity levels.
What Should You Know Before Using AeroBec Autohaler?
Contraindications
AeroBec Autohaler must not be used by anyone with a known hypersensitivity (allergy) to beclometasone dipropionate, norflurane (the propellant), ethanol, or any other component of the formulation. Allergic reactions to inhaled corticosteroids are rare but can manifest as facial swelling, tongue or throat swelling, difficulty swallowing, urticaria (hives), breathing difficulties, or sudden faintness. If any of these symptoms occur after using the inhaler, stop use immediately and seek emergency medical attention.
AeroBec Autohaler is specifically designed for the long-term preventive management of asthma and should never be used as a primary treatment for acute asthma attacks or status asthmaticus. In acute bronchospasm, patients require a rapid-acting bronchodilator such as salbutamol (albuterol). Using an inhaled corticosteroid alone during an acute attack is ineffective and potentially dangerous, as it does not provide the immediate bronchodilation needed to relieve airway obstruction.
Warnings and Precautions
AeroBec Autohaler is for preventive use only. It will not relieve an acute asthma attack. Always carry a separate fast-acting reliever inhaler (e.g., salbutamol) for emergency use. If you find that your reliever inhaler is needed more frequently, or if your asthma symptoms are worsening, contact your doctor promptly as your treatment may need to be adjusted.
Consult your doctor or pharmacist before using AeroBec Autohaler if you have any of the following conditions or circumstances:
- Active or latent tuberculosis (TB): Corticosteroids can suppress the immune response and may allow reactivation of latent TB or worsening of active tuberculosis infection. Your doctor may need to screen for TB before initiating inhaled corticosteroid therapy.
- Any form of lung infection: Active fungal, bacterial, or viral respiratory infections should be adequately treated before starting or adjusting inhaled corticosteroid therapy, as immunosuppressive effects could allow infections to progress.
- Switching from oral corticosteroid tablets: If you are transitioning from systemic corticosteroid therapy (such as prednisolone tablets) to inhaled beclometasone, your doctor will gradually reduce the oral corticosteroid dose while monitoring your response. During this transition, you may experience withdrawal symptoms such as fatigue, weakness, joint pain, muscle pain, nausea, or worsening of allergic conditions (such as eczema or rhinitis) even though your asthma symptoms may be improving. Contact your doctor immediately if these symptoms occur. You may also need supplementary systemic corticosteroid cover during periods of physiological stress (such as severe infections, surgery, or trauma) because your adrenal glands may not yet have recovered full cortisol-producing capacity.
- Worsening asthma control: If you notice that your AeroBec Autohaler is becoming less effective—for example, you need your reliever inhaler more often, or your peak flow readings are declining—consult your doctor. Your asthma treatment plan may need to be stepped up.
- Visual disturbances: If you experience blurred vision or other visual disturbances while using inhaled corticosteroids, consult your doctor. Systemic corticosteroid effects, though uncommon with inhaled formulations at standard doses, can include increased intraocular pressure and cataract formation.
Children receiving long-term treatment with inhaled corticosteroids should have their height (growth) monitored regularly. Some studies have shown that high-dose inhaled corticosteroids may slow growth velocity in children, although most children eventually reach their predicted adult height. Your doctor will prescribe the lowest effective dose to minimize this risk. The benefits of well-controlled asthma generally outweigh the small potential impact on growth.
Pregnancy and Breastfeeding
If you are pregnant, planning to become pregnant, or breastfeeding, consult your doctor before using AeroBec Autohaler. Clinical experience with beclometasone dipropionate during human pregnancy is limited compared to some other inhaled corticosteroids such as budesonide. However, major asthma guidelines—including GINA, BTS/SIGN, and ACOG (American College of Obstetricians and Gynecologists)—strongly recommend that pregnant women with asthma continue their controller therapy, including inhaled corticosteroids, because poorly controlled asthma poses significant risks to both mother and fetus, including pre-eclampsia, preterm birth, low birth weight, and neonatal hypoxia. The risks of uncontrolled asthma during pregnancy substantially outweigh the theoretical risks of inhaled corticosteroid use.
It is not known with certainty whether beclometasone dipropionate is excreted in human breast milk. However, given that inhaled beclometasone achieves very low systemic concentrations and that other corticosteroids are excreted in breast milk only in very small amounts, the risk to the nursing infant is considered minimal at therapeutic inhaled doses. The benefits of breastfeeding together with the clinical need for asthma control should be considered when making treatment decisions. Discuss the risks and benefits with your doctor.
Driving and Operating Machinery
AeroBec Autohaler has no known effects on the ability to drive or operate machinery. Beclometasone dipropionate does not cause sedation, drowsiness, or impaired cognitive function at therapeutic inhaled doses. However, as with any medication, you should be aware of your own response and avoid driving or operating machinery if you experience any unexpected symptoms that could impair your alertness or judgment.
Excipient Information
AeroBec Autohaler contains a small amount of ethanol (alcohol)—approximately 4.74 mg per inhalation. This amount is equivalent to less than 0.1 ml of beer or 0.05 ml of wine per dose and produces no perceptible effects. The propellant used is norflurane (HFA-134a), a hydrofluoroalkane that replaced older chlorofluorocarbon (CFC) propellants in accordance with the Montreal Protocol on ozone-depleting substances.
How Does AeroBec Autohaler Interact with Other Drugs?
Beclometasone dipropionate, the active ingredient in AeroBec Autohaler, is metabolized in part by the cytochrome P450 enzyme CYP3A4. Although systemic absorption from inhaled beclometasone is generally low, drugs that inhibit CYP3A4 can increase the amount of beclometasone reaching the systemic circulation, potentially raising the risk of corticosteroid side effects. It is important to inform your doctor, pharmacist, or nurse about all medications you are currently taking, including prescription medicines, over-the-counter drugs, herbal products, and dietary supplements.
Major Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| Ritonavir | Potent CYP3A4 inhibitor used in HIV treatment. Can significantly increase systemic exposure to beclometasone, raising the risk of adrenal suppression and Cushing’s syndrome | Concurrent use is not recommended unless the benefit outweighs the risk. If unavoidable, monitor closely for systemic corticosteroid effects. Consider alternative HIV or asthma therapies. |
| Cobicistat | Pharmacokinetic enhancer with potent CYP3A4 inhibition. Similar risk profile to ritonavir for increasing beclometasone systemic exposure | Avoid concurrent use if possible. If combination therapy is necessary, patients must be closely monitored for signs of adrenal suppression and systemic corticosteroid side effects. |
| Ketoconazole, Itraconazole | Strong azole antifungals that inhibit CYP3A4. Can increase systemic beclometasone levels and the risk of corticosteroid side effects | Use with caution. If concurrent treatment is needed, monitor for signs of systemic corticosteroid effects. Keep the treatment period as short as possible. |
Minor Interactions and Considerations
| Substance | Effect | Clinical Advice |
|---|---|---|
| Other CYP3A4 inhibitors (clarithromycin, erythromycin, verapamil, diltiazem) | Moderate CYP3A4 inhibitors that may modestly increase beclometasone systemic exposure | Generally safe at standard inhaled doses. Be aware of the potential interaction during prolonged concurrent use. |
| CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, phenobarbital) | May accelerate beclometasone metabolism, potentially reducing its anti-inflammatory efficacy | Monitor asthma control. A dose adjustment of the inhaled corticosteroid may be necessary if efficacy appears reduced. |
| Beta-blockers (non-selective, e.g., propranolol) | Not a direct interaction with beclometasone, but non-selective beta-blockers can worsen bronchospasm in asthmatic patients and reduce the effectiveness of beta2-agonist reliever inhalers | Non-selective beta-blockers are generally contraindicated in asthma. If a beta-blocker is medically essential, a cardioselective agent (e.g., bisoprolol) is preferred under close monitoring. |
Unlike oral corticosteroids such as prednisolone, inhaled beclometasone at standard therapeutic doses achieves very low systemic concentrations. Consequently, clinically significant drug interactions are considerably less common with the inhaled formulation than with oral corticosteroid therapy. Nevertheless, patients taking multiple medications should always discuss potential interactions with their healthcare provider.
What Is the Correct Dosage of AeroBec Autohaler?
Always use AeroBec Autohaler exactly as your doctor has instructed. Do not change the dose without consulting your doctor first. The medication must be used regularly every day, even during symptom-free periods, to maintain its preventive effect. The dosage should be adjusted to the lowest dose that effectively controls your asthma symptoms.
Adults and Children Over 12 Years
Standard Adult Dosing
The usual starting dose is 50 to 100 micrograms inhaled twice daily (morning and evening). Your doctor may initially prescribe a higher dose of 200 to 400 micrograms twice daily if your asthma is more severe or not adequately controlled. Once good asthma control is established, your doctor should gradually reduce the dose to the lowest amount that maintains symptom control. The maximum recommended daily dose is 800 micrograms (divided into two doses).
Children Aged 5 to 12 Years
Pediatric Dosing
The recommended dose is 50 micrograms twice daily (morning and evening). If necessary, your doctor may increase the dose, but the maximum daily dose for children in this age group is 200 micrograms. The dose should be individualized to the lowest amount that effectively controls the child’s asthma. Growth should be monitored regularly in children receiving long-term inhaled corticosteroid therapy.
| Patient Group | Starting Dose | Frequency | Maximum Daily Dose |
|---|---|---|---|
| Adults & children >12 years | 50–100 mcg per dose | Twice daily (morning & evening) | 800 mcg/day |
| Adults (severe asthma) | 200–400 mcg per dose | Twice daily (morning & evening) | 800 mcg/day |
| Children 5–12 years | 50 mcg per dose | Twice daily (morning & evening) | 200 mcg/day |
How to Use AeroBec Autohaler
If you are using the inhaler for the first time, or if it has not been used for 14 days or more, you must prime it by releasing two test sprays into the air (away from your face). To prime: remove the protective cap, raise the lever, then press the dose release button at the bottom of the mouthpiece. Repeat this process for the second test spray. After priming, push the lever back down—the inhaler is now ready for use.
Follow these steps carefully each time you use AeroBec Autohaler:
- Remove the protective cap by pulling on the back edge. The inhaler does not need to be shaken before use.
- Hold the inhaler upright and pull the lever up until it is fully raised. Continue holding the inhaler upright. Be careful not to block the air vent (located at the bottom of the inhaler) with your fingers.
- Breathe out fully as much as you comfortably can, away from the mouthpiece.
- Place the mouthpiece in your mouth and close your lips firmly around it. Breathe in slowly and deeply through the mouthpiece. The Autohaler will automatically release the medication as you inhale—you will hear a “click” and may taste the medicine. It is very important to continue breathing in after the click.
- Hold your breath for approximately 10 seconds, then breathe out slowly.
- Push the lever back down after each dose. If your doctor has prescribed more than one puff, repeat steps 2 through 5 for each additional dose.
- Replace the protective cap after use.
- Rinse your mouth with water and spit it out. Do not swallow the rinse water. This reduces the risk of oral thrush.
Do not use the manual dose release button when taking your medication. The Autohaler is designed to release the dose automatically when you breathe in. Using the manual button during treatment bypasses the breath-actuation mechanism and may result in poor drug delivery to the lungs.
Missed Dose
If you forget to take a dose, take it as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed dose and continue with your normal dosing schedule. Do not take a double dose to make up for a forgotten one. Consistency is important for the preventive effect of AeroBec Autohaler, so try to take your doses at the same times each day to help establish a routine.
Overdose
If you accidentally use more AeroBec Autohaler than prescribed, or if a child accidentally uses the medication, contact your doctor, emergency department, or poison control center for assessment and advice. A single acute overdose with inhaled beclometasone is unlikely to cause serious harm. However, chronic excessive dosing above recommended levels can lead to suppression of the hypothalamic-pituitary-adrenal (HPA) axis (adrenal suppression) and other systemic corticosteroid effects. If chronic overdose is suspected, adrenal function may need to be monitored, and the beclometasone dose should be reduced gradually under medical supervision to the minimum effective level.
What Are the Side Effects of AeroBec Autohaler?
Like all medicines, AeroBec Autohaler can cause side effects, although not everyone experiences them. Most side effects of inhaled beclometasone are local (affecting the mouth, throat, and airways) and are generally mild. Systemic (whole-body) side effects are uncommon at recommended doses but may occur with prolonged use at high doses. If you experience any troublesome or persistent side effects, discuss them with your doctor or pharmacist.
Swelling of the face, tongue, or throat; difficulty swallowing; hives (urticaria); breathing difficulties; or sudden feelings of faintness. These may be signs of a serious allergic reaction (angioedema). Also seek immediate medical help if you develop sudden, acute wheezing or breathlessness immediately after using the inhaler (paradoxical bronchospasm)—this is rare but requires prompt treatment.
Common
- Oral thrush (candidiasis of the mouth, larynx, and throat)—a fungal infection causing white patches, soreness, or altered taste. Risk is reduced by rinsing the mouth with water after each inhalation and spitting out.
- Throat irritation and hoarseness (dysphonia)—caused by local deposition of the corticosteroid on the vocal cords and oropharyngeal tissues
Uncommon
- Urticaria (hives)
- Eczema
- Cough
- Worsening asthma symptoms
- Tremor
- Headache
- Dizziness
Rare
- Nausea
Very Rare
- Cushing’s syndrome (moon face, central obesity, skin thinning, bruising, stretch marks, high blood pressure, and sometimes diabetes)—associated with prolonged use at high doses
- Adrenal suppression (reduced cortisol production by the adrenal glands)
- Decreased bone mineral density (osteoporosis risk with prolonged high-dose use)
- Eye problems including cataracts and glaucoma
- Growth retardation in children and adolescents
Not Known
- Blurred vision
- Sleep disturbances, depression, anxiety, restlessness, overactivity, irritability, or behavioral changes (these psychological effects are seen more frequently in children)
The risk of systemic side effects depends on the dose, the duration of treatment, concurrent use of other corticosteroids, and individual patient factors. At the recommended doses for AeroBec Autohaler (up to 400 micrograms daily for most patients), systemic side effects are uncommon. The GINA 2024 report emphasizes that the benefits of well-controlled asthma with inhaled corticosteroids far outweigh the risks of their side effects at standard therapeutic doses.
If you notice any side effects not listed here, or if any side effect becomes serious, please inform your doctor or pharmacist. Reporting suspected adverse reactions helps to continuously monitor the benefit-risk balance of medicines.
How Should You Store AeroBec Autohaler?
Proper storage of AeroBec Autohaler ensures that the medication remains effective and safe throughout its shelf life. Store the inhaler at room temperature, not exceeding 30°C (86°F). Avoid placing the inhaler in direct sunlight, near radiators or other heat sources, or in extremely hot environments such as the interior of a car on a warm day. The pressurized canister contains a propellant (norflurane) under pressure and must not be punctured, damaged, or exposed to excessive force or temperatures above the recommended limit.
AeroBec Autohaler is engineered to deliver accurate doses at temperatures as low as −10°C (14°F), making it reliable for use in cold weather conditions. However, if the inhaler has been stored in very cold conditions, allow it to return to room temperature before use for optimal performance.
Keep the inhaler out of the sight and reach of children. Do not use AeroBec Autohaler after the expiry date printed on the label and carton (after “EXP”). The expiry date refers to the last day of the stated month. Each inhaler contains 200 metered doses.
Do not dispose of medicines via household waste or wastewater. Ask your pharmacist about proper disposal methods for medications that are no longer needed. Appropriate disposal helps protect the environment, as the pressurized canister contains the fluorinated greenhouse gas norflurane (HFA-134a).
Cleaning the Inhaler
To keep the Autohaler in good working condition, wipe the outside of the mouthpiece regularly with a clean, dry cloth or tissue. Do not insert the cloth into the inhaler, as this may damage the internal mechanism. Do not disassemble the inhaler. Do not allow the inhaler to come into contact with water or other liquids, as moisture can affect the breath-actuation mechanism and the medication formulation.
What Does AeroBec Autohaler Contain?
Active Ingredient
Each metered dose of AeroBec Autohaler delivers 50 micrograms of anhydrous beclometasone dipropionate. Beclometasone dipropionate is a synthetic halogenated glucocorticosteroid that has been used for the treatment of asthma since the early 1970s. It is a prodrug that is activated locally in the lung tissue, which contributes to its favorable benefit-to-risk ratio when used by inhalation.
Inactive Ingredients (Excipients)
- Norflurane (HFA-134a): The propellant that generates the aerosol for drug delivery. Norflurane is a hydrofluoroalkane (HFA) propellant that replaced older chlorofluorocarbon (CFC) propellants as part of the global phase-out of ozone-depleting substances under the Montreal Protocol. Each AeroBec Autohaler 50 mcg/dose inhaler contains approximately 13.13 g of norflurane, equivalent to approximately 0.019 tonnes of CO2 equivalent (GWP = 1430).
- Ethanol (96%): Used as a co-solvent to help dissolve beclometasone dipropionate in the propellant. Each inhalation contains approximately 4.74 mg of ethanol, an amount that is clinically negligible (equivalent to less than 0.1 ml of beer).
Packaging
AeroBec Autohaler is supplied as a single inhaler unit containing 200 metered doses. The device features a built-in breath-actuation mechanism with a lever that must be raised before each inhalation and a protective cap to keep the mouthpiece clean when not in use. The inhaler is manufactured by Norton (Waterford) Limited, trading as Teva Pharmaceuticals Ireland, in Waterford, Ireland.
Frequently Asked Questions
The key difference is the breath-actuated delivery mechanism. A regular metered-dose inhaler (MDI) requires you to press down on the canister and breathe in at exactly the same time, which many people find difficult. The AeroBec Autohaler uses a spring-loaded mechanism that automatically detects your inhalation and releases the dose at the right moment. This eliminates the need for hand-breath coordination and has been shown to improve medication delivery to the lungs, particularly in patients who struggle with conventional inhaler technique.
No. AeroBec Autohaler is a preventive (controller) medication designed for daily use to reduce airway inflammation and prevent asthma symptoms from occurring. It does not work quickly enough to relieve acute asthma symptoms. You should always have a separate fast-acting reliever inhaler, such as salbutamol (albuterol), available for emergency use during asthma attacks. If you find yourself needing your reliever inhaler more often, contact your doctor as your preventer treatment may need to be adjusted.
Rinsing your mouth with water and spitting it out after each use removes residual beclometasone dipropionate from the mouth and throat. The corticosteroid deposited in the oropharynx can suppress local immune defenses, creating an environment favorable for fungal overgrowth—specifically oral candidiasis (thrush), which appears as white patches and soreness in the mouth. It can also cause hoarseness by affecting the vocal cords. Rinsing and spitting (not swallowing) is one of the simplest and most effective ways to prevent these common local side effects.
AeroBec Autohaler works gradually by reducing airway inflammation over time. Some patients may notice slight improvement within a few days of starting regular use, but the full protective effect typically takes approximately 7 to 10 days of consistent daily use to develop. This is why it is crucial to use the inhaler every day as prescribed, even when you feel well, and not to stop treatment because you are not experiencing immediate effects.
You should not stop using AeroBec Autohaler without discussing it with your doctor, even if your asthma symptoms have improved. The improvement in your symptoms is a sign that the medication is working effectively. Stopping treatment abruptly can lead to a return of airway inflammation and worsening of asthma symptoms within days to weeks. If your asthma has been well controlled for a prolonged period, your doctor may consider gradually reducing the dose to find the lowest effective maintenance dose, but this should always be done under medical supervision with careful monitoring of lung function and symptoms.
Yes. “Beclometasone” and “beclomethasone” are two accepted spellings of the same drug. “Beclometasone” is the International Nonproprietary Name (INN) used in most countries and by the WHO, while “beclomethasone” is the United States Adopted Name (USAN) used primarily in American publications and by the FDA. They refer to exactly the same active pharmaceutical ingredient. The full chemical name of the drug in AeroBec Autohaler is beclometasone dipropionate (INN) or beclomethasone dipropionate (USAN).
References
This article is based on the following peer-reviewed sources, international guidelines, and regulatory documents:
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. GINA Report 2024. Available at: ginasthma.org. The definitive international guideline for asthma management, recommending inhaled corticosteroids as the foundation of controller therapy.
- British Thoracic Society / Scottish Intercollegiate Guidelines Network (BTS/SIGN). British Guideline on the Management of Asthma. SIGN 158; 2024. Comprehensive UK guideline including stepwise approach to asthma treatment and inhaler device selection.
- European Medicines Agency (EMA). Beclometasone dipropionate – Summary of Product Characteristics. EMA; 2024. Official European regulatory documentation for beclometasone dipropionate inhalation products.
- British National Formulary (BNF). Beclometasone dipropionate Monograph. NICE/BNF; 2024. Authoritative UK drug reference covering indications, dosing, interactions, and side effects.
- National Institute for Health and Care Excellence (NICE). Asthma: diagnosis, monitoring and chronic asthma management. NICE Guideline NG80; updated 2024. UK evidence-based guideline for asthma care in adults and children.
- World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd edition; 2023. Beclometasone dipropionate is listed as an essential medicine for respiratory conditions.
- Newman SP, Weisz AWB, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax. 1991;46(10):712–716. doi:10.1136/thx.46.10.712. Landmark study demonstrating improved lung deposition with breath-actuated inhalers.
- Crompton GK, Barnes PJ, Broeders M, et al. The need to improve inhalation technique in Europe: A report from the Aerosol Drug Management Improvement Team. Respiratory Medicine. 2006;100(9):1479–1494. doi:10.1016/j.rmed.2006.01.008. Review of inhaler technique challenges and device solutions.
- Adams NP, Bestall JC, Lasserson TJ, Jones P, Cates CJ. Beclomethasone versus placebo for chronic asthma. Cochrane Database of Systematic Reviews. 2005;(1):CD002738. doi:10.1002/14651858.CD002738.pub2. Cochrane systematic review confirming efficacy of inhaled beclometasone in asthma.
- U.S. Food and Drug Administration (FDA). Beclomethasone Dipropionate Prescribing Information. FDA; 2024. Includes approved indications, dosing, warnings, and drug interaction information for the US market.
Editorial Team
This article has been written and reviewed by the iMedic medical editorial team according to our strict editorial standards. Our team consists of licensed physicians, pharmacists, and medical researchers with expertise in clinical pharmacology, pulmonology, and respiratory medicine.
Content developed by iMedic's medical writing team based on current international guidelines (WHO, EMA, FDA, BNF, GINA, BTS/SIGN, NICE) and peer-reviewed pharmacological research.
Independently reviewed and fact-checked by the iMedic Medical Review Board, comprising board-certified specialists in clinical pharmacology, pulmonary medicine, and respiratory therapy.
All medical claims are supported by Level 1A evidence (systematic reviews, meta-analyses, and randomized controlled trials) following the GRADE evidence framework.
iMedic receives no commercial funding from pharmaceutical companies. All content is editorially independent with no conflicts of interest.